title: Temperature Effects on Kinetics of KV11.1 Drug Block Have Important Consequences for In Silico Proarrhythmic Risk Prediction.
abstract: Drug block of voltage-gated potassium channel subtype 11.1 human ether-a-go-go related gene (Kv11.1) (hERG) channels, encoded by the KCNH2 gene, is associated with reduced repolarization of the cardiac action potential and is the predominant cause of acquired long QT syndrome that can lead to fatal cardiac arrhythmias. Current safety guidelines require that potency of KV11.1 block is assessed in the preclinical phase of drug development. However, not all drugs that block KV11.1 are proarrhythmic, meaning that screening on the basis of equilibrium measures of block can result in high attrition of potentially low-risk drugs. The basis of the next generation of drug-screening approaches is set to be in silico risk prediction, informed by in vitro mechanistic descriptions of drug binding, including measures of the kinetics of block. A critical issue in this regard is characterizing the temperature dependence of drug binding. Specifically, it is important to address whether kinetics relevant to physiologic temperatures can be inferred or extrapolated from in vitro data gathered at room temperature in high-throughout systems. Here we present the first complete study of the temperature-dependent kinetics of block and unblock of a proarrhythmic drug, cisapride, to KV11.1. Our data highlight a complexity to binding that manifests at higher temperatures and can be explained by accumulation of an intermediate, non-blocking encounter-complex. These results suggest that for cisapride, physiologically relevant kinetic parameters cannot be simply extrapolated from those measured at lower temperatures; rather, data gathered at physiologic temperatures should be used to constrain in silico models that may be used for proarrhythmic risk prediction.
authors.affiliation: Computational Cardiology, Victor Chang Cardiac Research Institute, Darlinghurst, Australia (M.J.W., S.A.M., J.I.V., A.P.H.); and St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia (S.A.M., J.I.V., A.P.H.).
authors.forename: Monique J
authors.initials: MJ
authors.lastname: Windley
authors.affiliation: Computational Cardiology, Victor Chang Cardiac Research Institute, Darlinghurst, Australia (M.J.W., S.A.M., J.I.V., A.P.H.); and St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia (S.A.M., J.I.V., A.P.H.).
authors.forename: Stefan A
authors.initials: SA
authors.lastname: Mann
authors.affiliation: Computational Cardiology, Victor Chang Cardiac Research Institute, Darlinghurst, Australia (M.J.W., S.A.M., J.I.V., A.P.H.); and St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia (S.A.M., J.I.V., A.P.H.).
authors.forename: Jamie I
authors.initials: JI
authors.lastname: Vandenberg
authors.affiliation: Computational Cardiology, Victor Chang Cardiac Research Institute, Darlinghurst, Australia (M.J.W., S.A.M., J.I.V., A.P.H.); and St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia (S.A.M., J.I.V., A.P.H.) a.hill@victorchang.edu.au.
authors.forename: Adam P
authors.initials: AP
authors.lastname: Hill
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000473:pathology*; D016466:CHO Cells; D020117:Cisapride / Q000494:pharmacology*; D003198:Computer Simulation; D006224:Cricetinae; D003412:Cricetulus; D000072237:ERG1 Potassium Channel / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015640:Ion Channel Gating / Q000187:drug effects; D007700:Kinetics; D008954:Models, Biological; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D012307:Risk Factors; D013696:Temperature
chemical_list: D000072237:ERG1 Potassium Channel; C000606913:KCNH2 protein, human; D026902:Potassium Channel Blockers; D020117:Cisapride